Advertisement
Product › Details
ANX005 (Annexon Biosciences)
Next higher product group | therapeutic antibody | |
Status | 2018-12-19 development p1 existent | |
Organisation | Annexon Biosciences Inc. | |
Group | Annexon Inc. (ANNX) | |
Annexon Biosciences Inc.. (12/19/18). "Press Release: Annexon Biosciences Closes $75 Million Financing". South San Francisco, CA.
Proceeds support the clinical development of multiple product candidates inhibiting the classical complement pathway in autoimmune, ophthalmic and neurodegenerative disorders
Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing. The financing was led by new investor Bain Capital Life Sciences, with participation by Surveyor Capital (a Citadel company), and Adage Capital Partners. Existing investors, including NEA, Blackstone Life Sciences, Novartis Venture Fund and Satter Investment Management, also participated in the round.
“The classical complement pathway plays a central role in immunity. Malfunction or disruption of this pathway is at the core of many diseases and represents an attractive target for therapeutic intervention,” said Doug Love, Esq., Chief Executive Officer and President of Annexon. “We have made great strides in building a portfolio of product candidates across multiple indications over the past two years. Proceeds from this financing will fund our lead programs in antibody-mediated autoimmune, ophthalmic and neurodegenerative indications through several clinical stages, including completion of proof-of-concept trials. Further, these funds will also support the rapid advancement of our next generation drug candidates in autoimmune and neurodegenerative settings.”
Annexon’s lead programs are ANX005, a monoclonal antibody drug candidate designed for treatment in autoimmune and neurodegenerative diseases, and ANX007 IVT, an antigen binding fragment (Fab) drug candidate designed for use in ophthalmic settings, currently in Phase 1b proof-of-principle studies that are expected to read out in 2019.
“We are impressed by the progress made by the Annexon team in the field of classical complement to address diseases of high unmet need,” said Ricky Sun, Ph.D., a Partner at Bain Capital Life Sciences. “We look forward to partnering with Doug and his team to advance the development of Annexon’s promising pipeline into transformative therapies for patients.” In conjunction with Bain Capital’s investment, Dr. Sun joined Annexon’s Board of Directors.
About Annexon Biosciences
Annexon Biosciences is creating and developing proprietary therapeutic products that modulate the classical complement pathway. Our pipeline is based on breakthrough research showing that the initiating molecule of the classical pathway, C1q, stimulates an immune-mediated attack that causes cell loss and tissue damage in a broad array of autoimmune, neurodegenerative and ophthalmic disorders. For more information, visit www.annexonbio.com.
Media Contact
Shai Biran, Ph.D.
MacDougall Biomedical Communications
sbiran@macbiocom.com
781-235-3060
Record changed: 2023-07-10 |
Advertisement
More documents for therapeutic antibody
- [1] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [2] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
- [3] WuXi Biologics. (1/11/24). "Press Release: WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates". Shanghai....
- [4] Calypso Biotech B.V.. (1/8/24). "Press Release: Calypso Enters into Agreement to Be Acquired by Novartis". Amsterdam....
- [5] SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai....
- [6] EMBL. (12/14/23). "Press Release: Using Artificial Intelligence to Discover Therapeutic Antibodies"....
- [7] Boehringer Ingelheim. (11/28/23). "Press Release: Boehringer Ingelheim and IBM Collaborate to Advance Generative AI and Foundation Models for Therapeutic Antibody Development". Ingelheim & Armonk, NY....
- [8] Roche. (10/23/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire Telavant". Basel....
- [9] Twist Bioscience Corporation. (9/27/23). "Press Release: Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases". South San Francisco, CA & Rafael, CA & Barcelona....
- [10] Adivo GmbH. (9/15/23). "Press Release: Adivo Joins Zoetis to Bring the Benefits of Species-specific Antibody Therapies to Pet Owners Worldwide". Puchheim & Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top